Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetes mellitus is a widespread disease with increasing prevalence worldwide. Patients with diabetes can develop multiple late complications such as neuropathy, retinopathy, nephropathy and cardiovascular comorbidities. So far, there are no reliable predictive tools or markers to estimate if, when and to what extent a patient with diabetes develops late complications. For the patients quality of life and for health economic reasons an improved risk assessment would be desirable. The prospective TUEDID study will characterize diabetic patients to look out for parameters the predict progression of diabetes and its complications.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TUEDID cohort |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic control (blood glucose) | Assessed as fasting blood glucose and HbA1C | At enrolment |
| Glycemic control (HbA1C) | Assessed as fasting HbA1C | At enrolment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Liver function | Parameters for liver function will be assessed (GOT, GPT, AP, Gamma-GT, Lipase, all [U/l]) | At enrolment |
| Renal function | Parameters for renal function will be assessed (Creatinine, Urea, Cystatin C, all [mg/dl]) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
People with or without diabetes who are treated at the University Hospital Tübingen
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas Fritsche, MD | Contact | +49 7071 29 80687 | andreas.fritsche@med.uni-tuebingen.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Tuebingen, Internal medicine IV | Recruiting | Tübingen | 72074 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| At enrolment |
| Glomerular filtration rate (GFR) | Glomerular filtration rate will be determined [ml/min/1,73 m²] | At enrolment |
| Lipid status | Parameters for evaluation of lipid status will be assessed (LDL, HDL, Cholesterol, triglycerides, all [mg/dl]) | At enrolment |
| Inflammation | Parameters to evaluate the inflammatory state will be assessed (CRP [mg/dl]) | At enrolment |
| Insulinemia | Insulin and C-peptide concentrations will be assessed [pmol/l] | At enrolment |
| Hormones | Parameters for evaluation of hormonal status will be assessed (TSH [mU/l]) | At enrolment |
| Hormones | Parameters for evaluation of hormonal status will be assessed (fT3 and fT4 [pmol/l]) | At enrolment |
| Hormones | Parameters for evaluation of hormonal status will be assessed (Cortisol [nmol/l]) | At enrolment |
| Urine parameters | Parameters from urine will be assessed (albumin, total protein, both [mg/l]) | At enrolment |
| Urine parameters | Parameters from urine will be assessed (creatinine [ml/min]) | At enrolment |
| Urine parameters | Parameters from urine will be assessed (urine sediment via microscopy) | At enrolment |
| Pancreas | Lipase and amlyase concentrations for evaluation of pancreas status will be assessed [U/l] | At enrolment |
| Coagulation | Parameters for evaluation of coagulation status will be assessed (INR, blood cell count) | At enrolment |
| Angiological examination | Angiological examination of parameters for vascular function | At enrolment |
| Measurement of height and weight | Height and weight will be measured and reported as BMI (kg/m^2) | At enrolment |
| Measurement of waist and hip circumference | Waist and hip circumference will be measured and reported as waist-to-hip ratio | At enrolment |
| Blood pressure | Blood pressure will be measured | At enrolment |
| Heart rate | Heart rate will be measured | At enrolment |
| Measurement of advanced glycation endproducts | Will be assessed by AGE reader | At enrolment |
| Body composition | Body fat content and lean mass will be assessed by bioimpedance analysis | At enrolment |
| Pulmonary function (optional) | Pulmonary function will optionally be assessed by Spiroergometric Performance Diagnostic | At enrolment |
| Retinal examination | Examination of diabetic rethinopathy by fundus photography or optionally by Optical Coherence Tomography Angiography | At enrolment |
| Anamnestic and Lifestyle questionnaire | Questions about physical activity, medical history and family background will be asked | At enrolment |
| cognitive testing | Cambridge Neuropsychological Test Automated Battery will be performed on tablet | At enrolment |
| Stool examination (single stool sample) | composition pof the gut microbiome will be assessed by 16S genome sequencing, bacterial metagenomic analysis, transcriptomics and metabolomics | At enrolment |
| Macronutrient absorption (optional) | Stool samples will be collected over multiple days and macronutrient absorption will be assessed by bomb calorimetry | At enrolment |
| Nasal and skin swab | nasal and skin swab will be collected and bacterial colonization analysed | At enrolment |